Combined medicine of cholesterylated TLR7 liposome and TLR9 agonist, composition and application thereof
Through the combined use of cholesterolized TLR7 liposomes and TLR9 agonists, the targeting and side effects of TLR7 agonists in anti-tumor treatment were solved, significantly reducing the number of tumor lung metastases and achieving better anti-tumor Effect.
Patent Information
- Application Number
- CN202411031479.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
The existing TLR7 agonists have poor targeting in anti-tumor treatment, have great side effects, and are poorly effective in anti-tumor treatment as a single agent, resulting in serious adverse reactions and insufficient efficacy in clinical applications.
Develop a cholesterolized TLR7 liposome, which is prepared as a 1V209-Cho-Lip liposome by modifying the TLR7 agonist 1V209 molecule 1V209-Cho-Cho-Lip liposome by combining it with TLR9 agonist to reduce the use of Low toxic side effects and improve anti-tumor effects.
In animal models, the combination of cholesterolized TLR7 liposomes and TLR9 agonists significantly reduced the number of nodules in tumor lung metastasis, showed good anti-tumor effects, reduced the toxic side effects of the drug, and improved the therapeutic effect.
Smart Images

Figure CN118949056A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of cancer immunotherapy, and specifically relates to a combined drug, composition and application of cholesterolated TLR7 liposome and TLR9 agonist. Background Art
[0002] Cancer immunotherapy aims to trigger host immune responses to fight tumor cells. A variety of immunotherapy approaches have been developed to stimulate innate and adaptive immunity in the tumor microenvironment. + T lymphocytes (CTLs) are considered to be the most effective killer cells, which eliminate tumor cells by secreting cytokines, releasing cytotoxic granules, etc. At the same time, the activation of CTLs mainly depends on antigen presenting cells (APCs), such as macrophages and dendritic cells (DCs), which present tumor-associated antigens (TAAs) to immature T cells, which is called the cross-presentation process.
[0003] DCs are key APCs required for priming naive T cells, and their ability to activate T cells depends mainly on the maturation state. Activation of DCs in tumor tissues may trigger the secretion of chemokines, causing antitumor effects. However, in most cases, DCs maintain an immunosuppressive phenotype due to the lack of a tumor microenvironment that stimulates DCs, especially a set of pattern recognition receptors (PRRs) in DCs. Therefore, agonists targeting PRRs can be used to reverse the immunosuppressive state of DCs and effectively elicit antitumor T cell responses. However, preclinical and clinical studies of PRR agonists as antitumor agents have revealed their limitations, and few of them have been approved by the FDA to treat malignant diseases. The main reason is the severe adverse reactions caused by most PRR agonists, such as imidazoquinolines (TLR7 / 8 agonists) and cyclic di-nuocleotides (STING agonists), which may be due to their systemic distribution, leading to the induction of pro-inflammatory cascades and severe immune-related toxicity.
[0004] Toll-like receptors (TLRs) belong to the PRRs family and can recognize conserved PAMPs expressed on foreign pathogens. These PAMPs can be selectively expressed on immune cells, including DCs, macrophages, and effector B / T cell populations. TLR7 is located in the endosomal membrane of innate immune cells and can be activated by viral guanosine- or uridine-rich single-stranded RNA to produce a strong Th-1 biased immune response by activating plasma cells and myeloid DC subsets. This makes TLR7 of dendritic cells have the function of inducing CD8 in tumor immunotherapy. +The function of T cell expansion and induction of adaptive anti-tumor immune response is a promising target. However, previous reports have shown that continuous systemic stimulation of TLR7 can lead to adverse side effects such as lymphopenia, splenomegaly, increased proinflammatory cytokines, and contraction of lymphocyte subsets, which greatly limits the clinical transformation of TLR7 agonists. Although studies have shown that nano-drug delivery systems can reduce the toxic and side effects of TLR7 agonists to a certain extent, most nano-drug delivery systems have the disadvantages of complex synthesis, low biocompatibility, and difficulty in clinical transformation. Therefore, it is urgent to develop a TLR7 agonist delivery system that is simple to synthesize, can significantly reduce its toxic and side effects, and is easier to clinically transform. At present, single drug use in tumor treatment often has poor efficacy. Combination therapy can not only enhance efficacy and reduce drug resistance, but also reduce drug toxicity and side effects. Therefore, it is also necessary to develop a combination of TLR7 agonists and other anti-tumor drugs to exert the best anti-tumor effect. Summary of the invention
[0005] In order to solve the problems of poor targeting, large side effects and poor efficacy of Toll-like receptor agonists in anti-tumor treatment as a single drug, the present invention provides a cholesterol-modified TLR7 liposome, which is prepared from a cholesterol-modified 1V209 molecule 1V209-Cho with lipid components and cholesterol, and the liposome is combined or combined with a TLR9 agonist for tumor treatment, thereby achieving the best anti-tumor effect while reducing toxic side effects.
[0006] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:
[0007] In a first aspect, the present invention provides an anti-tumor combination drug, which contains cholesterol-modified TLR7 liposomes and TLR9 agonists administered separately or simultaneously;
[0008] The cholesterol-modified TLR7 liposome is a 1V209-Cho-Lip liposome, comprising: a cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component and cholesterol; the structural formula of the 1V209-Cho is shown in Formula II,
[0009] Formula II:
[0010] In a second aspect, the present invention provides an anti-tumor pharmaceutical composition, which is composed of cholesterol-modified TLR7 liposomes and TLR9 agonists as active ingredients, and is added with pharmaceutically acceptable auxiliary ingredients;
[0011] The cholesterol-modified TLR7 liposome is a 1V209-Cho-Lip liposome, comprising: a cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component and cholesterol; the structural formula of the 1V209-Cho is shown in Formula II,
[0012] Formula II:
[0013] Furthermore, in the above-mentioned pharmaceutical composition, the auxiliary ingredient is at least one of a filler, a disintegrant, a wetting agent, an antioxidant, a chelating agent, a surfactant, a flavoring agent, a chelating agent, a pH adjuster or a pigment.
[0014] Furthermore, in the above-mentioned combined drug or pharmaceutical composition, the structural formula of 1V209 is as shown in Formula I,
[0015] Formula I:
[0016] Furthermore, in the above-mentioned combined drug or pharmaceutical composition, the lipid component is at least one of lecithin, hydrogenated lecithin or synthetic phospholipids.
[0017] The lipid component is preferably at least one of soybean lecithin or hydrogenated soybean lecithin.
[0018] The lipid component is most preferably hydrogenated soy phosphatidylcholine (HSPC).
[0019] Furthermore, in the above-mentioned combined drug or pharmaceutical composition, the molar ratio of the lipid component, cholesterol and 1V209-Cho is 60-70:27-37:1-8.
[0020] The preferred ratio among lipid components, cholesterol and 1V209-Cho in the liposome is a molar ratio of 63-68:30-35:2-4.
[0021] The most preferred ratio among the lipid components, cholesterol and 1V209-Cho in the liposome is 65:32:3.
[0022] Furthermore, in the above-mentioned combination drug or pharmaceutical composition, 1V209-Cho-Lip liposomes are prepared by rotary evaporation, ethanol injection or microfluidics.
[0023] The rotary evaporation method comprises the following steps: dissolving lipid components, cholesterol and 1V209-Cho in chloroform and methanol, forming a lipid film under rotary evaporation at 37-40° C., hydrating, and ultrasonicating to form liposomes 1V209-Cho-Lip.
[0024] Preferably, the hydration in the rotary evaporation method is hydration in PBS at 37-40° C. for 1-1.5 hours.
[0025] Preferably, the ultrasonic treatment in the rotary evaporation method is for 30 to 45 minutes; then, an 80W probe ultrasonic instrument is used for ultrasonic treatment for 2 to 3 minutes, and the ultrasonic frequency is on for 5 seconds / off for 5 seconds.
[0026] The ethanol injection method comprises the following steps: dissolving lipid components, cholesterol and 1V209-Cho in ethanol and dimethyl sulfoxide, then adding dropwise into an aqueous solution at 50-65°C, removing ethanol and dimethyl sulfoxide, and obtaining liposome 1V209-Cho-Lip.
[0027] Preferably, the temperature of the dropwise addition of ethanol by injection method is 55-60°C.
[0028] The microfluidic method includes the following steps: dissolving lipid components, cholesterol and 1V209-Cho in ethanol and dimethyl sulfoxide as organic phases, using physiological saline as aqueous phase, and the volume ratio of aqueous phase to organic phase is 3:1, and using microfluidic technology to prepare liposomes 1V209-Cho-Lip.
[0029] Furthermore, in the above-mentioned combined drug or pharmaceutical composition, the TLR9 agonist is at least one of CpG 1826, OND2216 or NOD1018.
[0030] Preferably, the TLR9 agonist is CpG 1826.
[0031] Furthermore, in the above-mentioned combined drug or pharmaceutical composition, the mass ratio of TLR9 agonist to 1V209-Cho-Lip liposome is 0.8-1.2:3.7-4.2.
[0032] The preferred mass ratio of the TLR9 agonist CpG 1826 to 1V209-Cho-Lip is 1:4.
[0033] In a third aspect, the present invention provides use of the above-mentioned combination drug or pharmaceutical composition in the preparation of anti-tumor drugs.
[0034] Furthermore, in the above application, the drug is a pharmaceutical preparation that is administered by injection, oral administration, nasal mucosa, lungs, rectum, oral mucosa or skin.
[0035] Furthermore, the drug is an injectable preparation, and the injection route is at least one of intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection, intramyocardial injection or intraperitoneal injection.
[0036] Furthermore, the drug is administered as a nasal spray.
[0037] Furthermore, in the above application, the tumor is at least one of melanoma, cervical cancer, colorectal cancer, breast cancer, pancreatic ductal carcinoma, liver cancer, gastric cancer, uterine cancer, ovarian cancer, testicular cancer, basal cell carcinoma or lung cancer.
[0038] Beneficial effects: The present invention uses cholesterol to modify the TLR7 agonist 1V209 to obtain the liposome 1V209-Cho-Lip, and further combines the liposome with the TLR9 agonist for tumor treatment. The results of animal experiments showed that in the mouse TC1 cervical cancer lung metastasis model, it was found that after 1V209-Cho-Lip and CpG 1826 were administered by nasal spray, the number of mouse lung metastasis tumor nodules was significantly reduced compared with the control group. In addition, 1V209-Cho-Lip and CpG 1826 were used in combination to treat B16F10 mouse melanoma lung metastasis. The results showed that the combined use of nasal spray can reduce the number of tumor lung metastasis nodules, and the combined administration by intramuscular injection can exert a better anti-tumor effect in the B16F10 mouse melanoma lung metastasis model. In conclusion, the cholesterol-modified TLR7 agonist 1V209-Cho-Lip obtained in the present invention combined with CpG 1826 has a good anti-tumor effect and provides a better combined drug administration method for cancer immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 Example 1A) Schematic diagram of the procedure for separate administration of CpG 1826 and 1V209-Cho-Lip in the B16F10 melanoma lung metastasis model; BC) Statistical graphs of the lungs and lung nodules of each group of mice after the treatment.
[0040] Figure 2 Example 2 A) Schematic diagram of the combined administration of 1V209-Cho-Lip and CpG 1826 in the TC1 cervical cancer lung metastasis model; BC) Lungs and weights of each group of mice after dissection after treatment; DF) Total number of tumor lung nodules (D), total number of lung nodules larger than 3 mm (E) and total number of lung nodules smaller than 3 mm in each group of mice. Data are expressed as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001).
[0041] Figure 3 Example 3 A) Schematic diagram of the co-administration procedure of 1V209-Cho-Lip and CpG 1826 in the B16F10 melanoma lung metastasis model; B) Lungs and their weights of mice in each group after dissection after treatment. Data are expressed as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001).
[0042] Figure 4This is an H&E image of mouse lungs after combined treatment with 1V209-Cho-Lip and CpG 1826 in the B16F10 melanoma lung metastasis model in Example 4. DETAILED DESCRIPTION
[0043] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clear, the present application is further described in detail below in combination with the implementation methods. Unless otherwise defined, all scientific and technological terms used herein have the same meanings as understood by ordinary technicians in the field.
[0044] 1V209 is a synthetic small molecule TLR7 agonist with anti-tumor effects, but it has strong systemic immunotoxicity. Combination therapy or drug combination can not only enhance the anti-tumor efficacy and reduce drug resistance, but also reduce drug toxicity and side effects. As an important member of the innate immune response process, TLR9 plays an important role in recruiting T cells to the tumor area. Therefore, the combination or combination of TLR7 agonists and TLR9 agonists for tumor treatment may exert the best anti-tumor effect.
[0045] In order to reduce the systemic immunotoxicity of TLR7 agonist 1V209, the present invention creatively provides a cholesterol-modified TLR7 liposome 1V209-Cho-Lip, which is prepared by conventional methods such as rotary evaporation, ethanol injection or microfluidics with cholesterol-modified 1V209 molecule 1V209-Cho and lipid components and cholesterol. The liposome is combined with TLR9 agonists such as CpG 1826, OND 2216 or NOD1018 for tumor treatment.
[0046] Wherein, the lipid component used is lecithin, hydrogenated lecithin or synthetic phospholipid. Further, the lipid component can be selected from soybean lecithin or hydrogenated soybean lecithin. The lipid component used in the embodiment of the present invention is hydrogenated soybean lecithin (HSPC).
[0047] In a specific embodiment of the present invention, the experimental results show that compared with CpG 1826 and 1V209-Cho-Lip alone, the combination of cholesterol-modified TLR7 liposome 1V209-Cho-Lip and TLR9 agonist CpG 1826 via nasal spray or intramuscular injection can significantly inhibit TC1 cervical cancer and B16F10 melanoma lung metastasis, and exhibits excellent anti-tumor effects in both tumor models.
[0048] Specific examples will be listed below to explain the scheme of the present invention. It will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area or the product instructions are used. Reagents or instruments used that do not indicate manufacturers are all conventional products that can be obtained commercially.
[0049] The main materials used in the following examples are as follows:
[0050] 1V209 was purchased from Selleck. Mouse TC1 cervical cancer cell line and B16F10 melanoma cell line were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI 1640 or DMEM medium (containing 10% fetal bovine serum (Gibco), 100 U Ml -1 Penicillin G and 100UmL -1 The cells were cultured with streptomycin sulfate (2% streptomycin sulfate) and cultured in an incubator at 37°C and 5% CO2. Female BALB / c mice and C57BL / 6 (6-8 weeks old, 18-20 g) were purchased from Huafukang Biotechnology Co., Ltd. (Beijing, China). All animal experiments were performed in accordance with the guidelines evaluated and approved by the Ethics Committee of Sichuan University.
[0051] Preparation of TLR7 agonist drug delivery system 1V209-Cho-Lip liposomes
[0052] (1) 1V209-Cho was prepared by the following synthetic means:
[0053] Step a, dissolving cholesterol, EDCI and DMAP in 10 mL DCM at a ratio of 1 eq: 2 eq: 0.1 eq, then adding boc-aminobutyric acid in an amount of 1.2 eq, reacting at room temperature for 24 hours, adding 25 mL DCM, extracting the organic layer, washing with brine, drying over anhydrous sodium sulfate, and concentrating in vacuo to obtain a crude product, which was purified by silica gel chromatography using petroleum ether / ethyl acetate to obtain product 1;
[0054] Product 1CHO-boc:
[0055] Step b, product 1 was dissolved in 5 mL DCM, and 10% TFA was added, stirred at room temperature for 1 h, 25 mL DCM was added, the organic layer was extracted, washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain product 2;
[0056] Product 2CHO-NH2:
[0057] Step c, 1V209, HATU and TEA are dissolved in 5 mL DMF in a ratio of 1 eq: 1.2 eq: 2 eq, and then the product 2 dissolved in DMF is added, the amount of product 2 is 1.2 eq, and after reacting at room temperature for 48 hours, the solvent DMF is removed by rotary evaporation to obtain a crude product, which is purified by silica gel chromatography using dichloromethane / methanol to obtain 1V209-Cho.
[0058] (2) The synthesis of 1V209-Cho-Lip liposomes was carried out by microfluidics: the lipid components HSPC, cholesterol and 1V209-Cho were dissolved in anhydrous ethanol and dimethyl sulfoxide at a molar ratio of 65:32:3 as the organic phase (the volume ratio of anhydrous ethanol and dimethyl sulfoxide was 10:1), and the concentration of 1V209-Cho in the organic phase was 0.8 μg / μL. Physiological saline was used as the aqueous phase, and the aqueous phase and the organic phase were quickly passed through the microfluidic chip at a volume ratio of 3:1 to obtain 1V209-Cho-Lip.
[0059] Example 1 Anticancer effect test of CpG 1826 and 1V209-Cho-Lip administered alone in B16F10 lung metastasis model
[0060] Eight-week-old C57BL / 6 mice were divided into three groups: PBS control group, CpG 1826 group, and 1V209-Cho-Lip group. The CpG 1826 dose was 250 μg / kg, and the 1V209-Cho-Lip dose was 1 mg / kg. Six mice were administered with nasal spray on days -7, 0, and 7, respectively. On day 1, 2×10 5 B16F10 cells were used to establish a melanoma lung metastasis model. On the 13th day, the mice were killed, the lungs were obtained by dissection, and photos were taken. The number of lung nodules was counted ( Figure 1 A). Compared with the PBS control group, CpG 1826 and 1V209-Cho-Lip groups alone could not significantly inhibit B16F10 melanoma lung metastasis after nasal administration ( Figure 1 B, C), the number of lung nodules in the two groups of mice treated with either drug alone was not significantly different from that in the PBS control group, indicating that nasal administration of CpG 1826 and 1V209-Cho-Lip alone could not effectively inhibit tumor lung metastasis.
[0061] Example 2 Anticancer effect test of 1V209-Cho-Lip combined with CpG 1826 in TC1 cervical cancer lung metastasis model
[0062] Eight-week-old C57BL / 6 mice were divided into two groups: a PBS control group and a 1V209-Cho-Lip+CpG 1826 combined administration group. The CpG 1826 dose was 250 μg / kg and the 1V209-Cho-Lip dose was 1 mg / kg. There were 9 mice in each group. The mice were injected with nasal spray on days -7, 0, and 7, and 2×10 5 TC1 cells were used to establish a TC1 cervical cancer lung metastasis model. On the 13th day, the mice were killed, the lungs were dissected, weighed and photographed, and the number of lung nodules was counted ( Figure 2 A). Compared with the PBS control group, 1V209-Cho-Lip combined with CpG 1826 can significantly inhibit TC1 cervical cancer lung metastasis after nasal administration ( Figure 2 B, C), the number of lung nodules in the drug group was significantly less than that in the PBS control group ( Figure 2 DF).
[0063] Example 3 Anticancer effect test of 1V209-Cho-Lip combined with CpG 1826 in B16F10 melanoma lung metastasis model
[0064] Eight-week-old C57BL / 6 mice were divided into two groups: a PBS control group and a 1V209-Cho-Lip+CpG 1826 combined administration group. The CpG 1826 dose was 250 μg / kg and the 1V209-Cho-Lip dose was 1 mg / kg. There were 9 mice in each group. The mice were injected intranasally or intramuscularly on days -7, 0, and 7, respectively. On day 1, 2×10 5 B16F10 cells were used to establish a B16F10 melanoma lung metastasis model. The mice were killed on the 13th day, and the lungs were obtained by dissecting the mice, weighing them and taking pictures ( Figure 3 A). 1V209-Cho-Lip combined with CpG 1826 can significantly inhibit B16F10 melanoma lung metastasis, whether administered intranasally or intramuscularly. Figure 3 B, C).
[0065] Example 4 H&E staining experiment of mouse lungs in the treatment of B16F10 melanoma lung metastasis model by 1V209-Cho-Lip combined with CpG 1826
[0066] The lung tissue obtained in Example 3 was fixed in 4% paraformaldehyde, and after 24 hours, it was embedded in paraffin and sectioned. The sections were placed in xylene I for 10 minutes, xylene II for 10 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, 95% alcohol for 5 minutes, 90% alcohol for 5 minutes, 80% alcohol for 5 minutes, 70% alcohol for 5 minutes, and washed with distilled water for dewaxing. Next, the sections were stained with Harris hematoxylin for 3-8 minutes, washed with tap water, differentiated with 1% hydrochloric acid alcohol for a few seconds, rinsed with tap water, blued with 0.6% ammonia water, and rinsed with running water. Then the sections were placed in eosin stain for 1-3 minutes. After staining, the sections were placed in 95% alcohol I for 5 minutes, 95% alcohol II for 5 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, xylene I for 5 minutes, and xylene II for 5 minutes to dehydrate and make them transparent. The sections were taken out of xylene, dried slightly, and sealed with neutral gum. Microscope examination and image acquisition and analysis. Results and Figure 3 Consistent with the results, H&E staining of mice showed that the number of lung nodules in the 1V209-Cho-Lip and CpG 1826 combined group was significantly less than that in the PBS control group ( Figure 4 ).
Claims
1. An anti-tumor combined drug, characterized in that: Containing cholesterolylated TLR7 liposomes and TLR9 agonists administered separately or simultaneously; The cholesterol-modified TLR7 liposome is a 1V209-Cho-Lip liposome, comprising: a cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component and cholesterol; the structural formula of the 1V209-Cho is shown in Formula II, Formula II:
2. An anti-tumor pharmaceutical composition, characterized in that: The active ingredients are cholesterol-modified TLR7 liposomes and TLR9 agonists, and pharmaceutically acceptable auxiliary ingredients are added; The cholesterol-modified TLR7 liposome is a 1V209-Cho-Lip liposome, comprising: a cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component and cholesterol; the structural formula of the 1V209-Cho is shown in Formula II, Formula II:
3. The pharmaceutical composition according to claim 2, characterized in that: The auxiliary component is at least one of a filler, a disintegrant, a wetting agent, an antioxidant, a chelating agent, a surfactant, a flavoring agent, a chelating agent, a pH regulator or a pigment.
4. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: The structural formula of 1V209 is shown in Formula I, Formula I:
5. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: The lipid component is at least one of lecithin, hydrogenated lecithin or synthetic phospholipids; the lipid component is preferably at least one of soybean lecithin or hydrogenated soybean lecithin; the lipid component is most preferably HSPC.
6. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: The molar ratio of lipid components, cholesterol and 1V209-Cho is 60-70:27-37:1-8; the preferred molar ratio is 63-68:30-35:2-4; and the most preferred ratio is 65:32:
3.
7. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: 1V209-Cho-Lip liposomes were prepared by rotary evaporation, ethanol injection or microfluidics.
8. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: The TLR9 agonist is at least one of CpG 1826, OND 2216 or NOD1018; preferably, the TLR9 agonist is CpG 1826.
9. The combined drug according to claim 1 or the pharmaceutical composition according to claim 2 or 3, characterized in that: The mass ratio of TLR9 agonist to 1V209-Cho-Lip liposome is 0.8-1.2:3.7-4.2; the preferred mass ratio is 1:
4.
10. Use of the combined drug according to any one of claims 1 and 4 to 9 or the pharmaceutical composition according to any one of claims 2 to 9 in the preparation of anti-tumor drugs.
11. The use according to claim 10, characterized in that: The drug is a pharmaceutical preparation that is administered by injection, oral administration, nasal mucosa, lungs, rectum, oral mucosa or skin; further, the drug is an injection preparation, and the injection route is at least one of intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection, intramyocardial injection or intraperitoneal injection; further, the drug is administered by nasal spray.
12. The use according to claim 10 or 11, characterized in that: The tumor is at least one of melanoma, cervical cancer, colorectal cancer, breast cancer, pancreatic ductal carcinoma, liver cancer, gastric cancer, uterine cancer, ovarian cancer, testicular cancer, basal cell carcinoma or lung cancer.
Citation Information
Cited By
Combination-therapy drug and composition of cholesterolylated TLR7 liposome and TLR9 agonist and use thereof
WO2026026205A1
